General Considerations for Clinical Studies – E8(R1)

On 7 April 2022 the FDA published the final guidance on ICH E8(R1) general considerations for clinical studies.

The ICH has the mission of achieving greater regulatory harmonization worldwide to ensure that safe, effective, and high-quality medicines are developed, registered, and maintained in the most resource-efficient manner. By harmonizing the regulatory expectations in regions around the world, ICH guidelines have substantially reduced duplicative clinical studies, prevented unnecessary animal studies, standardized safety reporting and marketing application submissions, and contributed to many other improvements in the quality of global drug development and manufacturing and the products available to patients.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /